A Phase 2 interventional study of ENERGI-F701 and Regaine in Female Pattern Baldness, Hair Loss and Alopecia, sponsored by Energenesis Biomedical Co., Ltd.. Completed at 1 site in Taiwan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.
Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Alopecia with a site in Taiwan — 3 open to participants now, 5 under way, 2 of them phase 3. Alopecia · Taiwan.
Among the 19 studies in Alopecia with a site in Taiwan, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2018, is the only one in phase 2, and was the 6th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →3 of the 19 studies in Alopecia with a site in Taiwan are open now. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 18–50 · Men only
Pfizer · Sites in Taiwan, United States, Canada and 8 more countries
Ages 12+
Eli Lilly and Company · Sites in Taiwan, United States, Argentina and 9 more countries
Ages 6–17
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 6
First in 2010; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 18 interventional studies, 400 across the 1 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Energenesis Biomedical Co., Ltd. has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07901426Hungkuang UniversityEvaluation of the Scalp Skin Care Effects of Premium Revitalizing Elixir and Topical 5% Minoxidil | 2026-12 |
| NCT07580521Taipei Medical University WanFang HospitalMicroneedling for Androgenic Alopecia: a Clinical Study | 2026-12-31 |
| NCT07248410Chang Gung Memorial HospitalA Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Alopecia with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of ENERGI-F701 Solution in female subjects with hair loss.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any subject meeting any of the exclusion criteria will be excluded from study participation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
Drug: ENERGI-F701
Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
Drug: Regaine
ENERGI-F701 are applied for treatment of hair loss.
Regaine are applied for treatment of hair loss.
The amount of hair loss
Change of the amount of hair loss at Week 12 from baseline.(hair loss is defined as the collection of hairs after combing at the study site)
Time frame: Week 12
The amount of hair loss at each post-treatment visit
Time frame: Week 2, 4, 6, 8, 10
The thickness and density of hair
Change of hair thickness and density measured by phototrichogram at each post-treatment visit
Time frame: Week 2, 4, 6, 8, 10, 12
Investigator assessment at each post-treatment visit
The hair loss will be assessed by the investigator using Investigator Photographic Assessment Questionnaire (IPAQ).The change from Baseline in hair growth will be assessed using the following 7-point scale: -3 = greatly decreased, -2 = moderately decreased, -1 = slightly decreased, 0 = no change, +1 = slightly increased, +2 = moderately increased, +3 = greatly increased.
Time frame: Week 2, 4, 6, 8, 10, 12
The hair wash/shed hair count at each post-treatment visit
Subjects will collect hairs full day, including after combing and hair-washing. Subjects should turn in these hair collections at each visit. The results will be averaged weekly.
Time frame: Week 2, 4, 6, 8, 10, 12
The subject satisfaction
Subject satisfaction evaluated by Women's Androgenic Alopecia Quality of Life Questionnaire (WAA-QOL) at each post-treatment visit from baseline. WAA-QOL is a sixteen-question questionnaire to evaluate subjects' quality of life influenced by hair loss. Each question will be assessed using the following 7-point scale: 0 = not at all, 1 = a little bit, 2 = somewhat, 3 = a good bit, 4 = quite a bit , 5 = very much, 6 = extremely.
Time frame: Week 2, 4, 6, 8, 10, 12
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Nov 2019, 18 months.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 18 months is above that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Energenesis Biomedical Co., Ltd. →